The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer

被引：0
|
作者：
Hjorth, Cathrine
Damkier, Per
Stage, Tore B.
Feddersen, Soren
Hamilton-Dutoit, Stephen
Ejlertsen, Bent
Lash, Timothy L.
Boggild, Henrik
Sorensen, Henrik
Cronin-Fenton, Deirdre
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P5-03-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-03-11
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Return-to-Work and Breast Cancer Survivorship Care
    Yuanlu Sun
    Cheryl L. Shigaki
    Jane M. Armer
    Current Breast Cancer Reports, 2020, 12 : 202 - 207
  • [22] Colitis in patients with breast carcinoma treated with taxane-based chemotherapy
    Li, ZY
    Ibrahim, NK
    Wathen, JK
    Wang, M
    Menchu, RPM
    Valero, V
    Theriault, R
    Buzdar, AU
    Hortobagyi, GN
    CANCER, 2004, 101 (07) : 1508 - 1513
  • [23] A literature-based meta-analysis taxane-based doublet versus single-agent taxane chemotherapy in patients with advanced breast cancer
    Xu, Hong-Bin
    Xu, Qing
    Li, Ling
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (06) : 1005 - 1013
  • [24] ABDOMINAL OBESITY AND WEIGHT GAIN AS A CONSEQUENCE OF TAXANE-BASED ADJUVANT CHEMOTHERAPY FOR BREAST CANCER
    Saloustros, E.
    Hatzidaki, D.
    Gioulbasanis, I.
    Koutsoudaki, K.
    Nikoloudaki, M.
    Margiolaki, A.
    Zeniodi, M.
    Ganotakis, E.
    Georgoulias, V.
    Mavroudis, D.
    ANNALS OF ONCOLOGY, 2010, 21 : 86 - 86
  • [25] GUT MICROBIOME AND SYMPTOM BURDEN IN WOMEN RECEIVING TAXANE-BASED CHEMOTHERAPY FOR BREAST CANCER
    Cherwin, Catherine
    Hoang, Jemmie
    ONCOLOGY NURSING FORUM, 2020, 47 (02)
  • [26] Relative dose intensity of taxane-based chemotherapy in patients with stage IV breast cancer
    Denduluri, N.
    Havrilesky, L.
    Bhor, M.
    Bhowmik, D.
    Morrow, P. K.
    Watson, H.
    Dhanda, R.
    Li, X.
    Chung, H.
    Saravanan, S.
    Barron, R.
    Crawford, J.
    CANCER RESEARCH, 2013, 73
  • [27] A 20-gene signature in predicting the chemoresistance of breast cancer to taxane-based chemotherapy
    He, Dong-Xu
    Xia, Yu-Dong
    Gu, Xiao-Ting
    Jin, Jian
    Ma, Xin
    MOLECULAR BIOSYSTEMS, 2014, 10 (12) : 3111 - 3119
  • [28] Relative dose intensity of taxane-based chemotherapy in breast cancer patients in a tertiary hospital
    Helwani, Amira M.
    Al Suleimani, Yousuf M.
    Al Baimani, Khalid
    Abdelrahman, Aly M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (08) : 1364 - 1371
  • [29] Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review
    Ricardo Fernandes
    Sasha Mazzarello
    Brian Hutton
    Risa Shorr
    Habeeb Majeed
    Mohammed FK Ibrahim
    Carmel Jacobs
    Michael Ong
    Mark Clemons
    Supportive Care in Cancer, 2016, 24 : 3633 - 3650
  • [30] Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy
    Liao, Yuqian
    Liao, Yulu
    Li, Jun
    Li, Junyu
    Fan, Ying
    Xu, Binghe
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 3801 - 3808
12345